TIG Advisors LLC lowered its position in Davita Inc (NYSE:DVA) by 56.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 378,460 shares of the company’s stock after selling 484,540 shares during the period. Davita comprises approximately 0.9% of TIG Advisors LLC’s investment portfolio, making the stock its 20th biggest position. TIG Advisors LLC owned approximately 0.24% of Davita worth $21,292,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the business. Oregon Public Employees Retirement Fund raised its position in shares of Davita by 0.5% in the first quarter. Oregon Public Employees Retirement Fund now owns 36,727 shares of the company’s stock worth $1,994,000 after acquiring an additional 185 shares during the period. Oppenheimer & Co. Inc. raised its position in shares of Davita by 1.6% in the second quarter. Oppenheimer & Co. Inc. now owns 12,600 shares of the company’s stock worth $709,000 after acquiring an additional 201 shares during the period. Piedmont Investment Advisors Inc. raised its position in shares of Davita by 3.3% in the first quarter. Piedmont Investment Advisors Inc. now owns 6,974 shares of the company’s stock worth $379,000 after acquiring an additional 225 shares during the period. Creative Planning raised its position in shares of Davita by 3.6% in the second quarter. Creative Planning now owns 7,231 shares of the company’s stock worth $407,000 after acquiring an additional 250 shares during the period. Finally, Commonwealth Equity Services LLC raised its position in shares of Davita by 2.3% in the second quarter. Commonwealth Equity Services LLC now owns 11,337 shares of the company’s stock worth $637,000 after acquiring an additional 251 shares during the period. Institutional investors and hedge funds own 90.71% of the company’s stock.
A number of brokerages have weighed in on DVA. Robert W. Baird downgraded shares of Davita from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $70.00 to $65.00 in a research report on Friday, July 26th. SunTrust Banks restated a “hold” rating and set a $68.00 price target on shares of Davita in a research report on Wednesday, September 11th. William Blair downgraded shares of Davita from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 11th. TheStreet upgraded shares of Davita from a “c+” rating to a “b-” rating in a research report on Wednesday, July 24th. Finally, UBS Group reduced their price target on shares of Davita from $61.00 to $60.00 and set a “neutral” rating for the company in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $67.31.
Davita (NYSE:DVA) last issued its quarterly earnings data on Thursday, August 1st. The company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.10 by $0.12. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. The business’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.05 EPS. Equities research analysts predict that Davita Inc will post 4.78 earnings per share for the current fiscal year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: How to interpret the current ratio
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.